Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety

Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...

ATFX Demonstrates Consistent Strong Performance in Q3 2024 Finance Magnates Data

ATFX Demonstrates Consistent Strong Performance in Q3 2024 Finance Magnates Data

HONG KONG, Dec. 5, 2024 /PRNewswire/ -- ATFX, ranked 5th in the Finance Magnates Q3 2024 report, showcased impressive performance with total trading volumes reaching $733.4 billion on its MT4/MT5 platforms. This substantial figure highlights ATFX's...

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial...

Hisense Ranks Global No.2 in Q3 2024 High-End TV Market

Hisense Ranks Global No.2 in Q3 2024 High-End TV Market

QINGDAO, China, Dec. 2, 2024 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, is reaping the rewards of its premium TV strategy, ranking second with a third-quarter global high-end TV market share of 24%...

Global Focus INC-5 Conference: Niutech Demonstrates 10,000-ton Continuous Plastic Pyrolysis Technology and Complete Equipment

Global Focus INC-5 Conference: Niutech Demonstrates 10,000-ton Continuous Plastic Pyrolysis Technology and Complete Equipment

JINAN, China, Dec. 2, 2024 /PRNewswire/ -- From November 25th to December 1st, 2024, the fifth session of the Intergovernmental Negotiating Committee on Plastic Pollution (INC-5) has been held in the Busan Exhibition & Convention Center in South...

Motiff Demonstrates Superior Performance of MLLM in Evaluation Study

Motiff Demonstrates Superior Performance of MLLM in Evaluation Study

SAN JOSE, Calif., Nov. 27, 2024 /PRNewswire/ -- Motiff Technologies announced the successful development of MLLM by Motiff, a specialized multimodal large language model designed to revolutionize user interface (UI) design. This innovative AI model...

LifeSignals Receives FDA 510(k) Approval for UbiqVue™ 2A Multiparameter System

LifeSignals Receives FDA 510(k) Approval for UbiqVue™ 2A Multiparameter System

Cloud-Based System, Featuring Wearable Biosensor with Chest-Based SpO2, Enables Active Patient Monitoring Across Hospital and Out-of-hospital Care Settings Replaces time-consuming manual spot checking with continuous, near real-time active patient...

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland, Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven...

  • 1
  • 2
  • 3
  • menu
    menu